Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease

Epidemiology

Volumn 21, Issue 1, 2010, Pages 87-94

  Manthripragada, Angelika D ^a   Costello, Sadie ^a,b   Cockburn, Myles G ^c   Bronstein, Jeff M ^d   Ritz, Beate ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS; DIMPYLATE; DNA; PARATHION;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC INFORMATION SYSTEM; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; WILD TYPE;

AGRICULTURE; ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; CALIFORNIA; ENVIRONMENTAL EXPOSURE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; PHOSPHORIC ACID ESTERS; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 73849096275     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181c15ec6     Document Type: Article

References (47)

1. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson disease and exposure to pesticides. Neurotoxicology. 2000; 21:435-440.
2. Hancock DB, Martin ER, Mayhew GM, et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol. 2008;8:6.
3. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology. 1996;46:1275-1284.
4. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med. 2003;54: 371-392.
5. Li WF, Costa LG, Richter RJ, et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics. 2000;10:767-779.
6. Pond AL, Chambers HW, Chambers JE. Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. Toxicol Lett. 1995;78:245-252.
7. Kang GA, Bronstein JM, Masterman DL, et al. Clinical characteristics in early Parkinson disease in a central California population-based study. Mov Disord. 2005;20:1133-1142.
8. Goldberg DW, Wilson JP, Knoblock CA, Ritz B, Cockburn MG. An effective and efficient approach for manually improving geocoded data. Int J Health Geogr. 2008;7:60.
9. Rull RP, Ritz B. Historical pesticide exposure in California using pesticide use reports and land-use surveys: an assessment of misclassification error and bias. Environ Health Perspect. 2003;111:1582-1589.
10. Chester G, Ward RJ. Occupational exposure and drift hazard during aerial application of paraquat to cotton. Arch Environ Contam Toxicol. 1984;13:551-563.
11. MacCollom GB, Currier WW, Baumann GL. Drift comparisons between aerial and ground orchard application. J Econ Entomol. 1986;79:459-464.
12. McElroy JA, Remington PL, Trentham-Dietz A, Robert SA, Newcomb PA. Geocoding addresses from a large population-based study: lessons learned. Epidemiology. 2003;14:399-407.
13. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met- Leu 54 polymorphism is associated with Parkinson disease. J Neurol Sci. 2001;184:179-182.
14. O'Leary KA, Edwards RJ, Town MM, Boobis AR. Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics. 2005;15:51-60.
15. Costa L, ed. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. New York: Springer; 2002.
16. Dick FD, De Palma G, Ahmadi A, et al. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup Environ Med. 2007;64:673-680. (Pubitemid 47488094)
17. Fong CS, Cheng CW, Wu RM. Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurol Taiwan. 2005;14:55-60.
18. Momose Y, Murata M, Kobayashi K, et al. Association studies of multiple candidate genes for Parkinson disease using single nucleotide polymorphisms. Ann Neurol. 2002;51:133-136.
19. Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology. 1999;52:1467-1471.
20. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson disease. Nat Neurosci. 2000;3:1301-1306.
21. Thiruchelvam M, McCormack A, Richfield EK, et al. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson disease phenotype. Eur J Neurosci. 2003;18:589-600.
22. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci. 2000;20:9207-9214. (Pubitemid 32042923)
23. Brighina L, Frigerio R, Schneider NK, et al. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology. 2008;70:1461-1469.
24. Firestone JA, Smith-Weller T, Franklin G, Swanson P, Longstreth WT Jr, Checkoway H. Pesticides and risk of Parkinson disease: a populationbased case-control study. Arch Neurol. 2005;62:91-95.
25. Kamel F, Tanner C, Umbach D, et al. Pesticide exposure and selfreported Parkinson's disease in the agricultural health study. Am J Epidemiol. 2007;165:364-374. (Pubitemid 46254589)
26. Shahar E, Andraws J. Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning. Eur J Paediatr Neurol. 2001;5: 261-264.
27. Shahar E, Bentur Y, Bar-Joseph G, Cahana A, Hershman E. Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning. Pediatr Neurol. 2005;33:378-382.
28. Davis KL, Yesavage JA, Berger PA. Single case study. Possible organophosphate-induced parkinsonism. J Nerv Ment Dis. 1978;166: 222-225.
29. Lee S, McLaughlin R, Harnly M, Gunier R, Kreutzer R. Community exposures to airborne agricultural pesticides in California: ranking of inhalation risks. Environ Health Perspect. 2002;110:1175-1184.
30. Harnly M, McLaughlin R, Bradman A, Anderson M, Gunier R. Correlating agricultural use of organophosphates with outdoor air concentrations: a particular concern for children. Environ Health Perspect. 2005;113:1184-1189.
31. Lewis RG, Fortune CR, Willis RD, Camann DE, Antley JT. Distribution of pesticides and polycyclic aromatic hydrocarbons in house dust as a function of particle size. Environ Health Perspect. 1999;107:721-726.
32. Eskenazi B, Bradman A, Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect. 1999;107:409-419.
33. Rauh VA, Garfinkel R, Perera FP, et al. Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics. 2006;118:e1845-e1859.
34. Rusyniak DE, Nanagas KA. Organophosphate poisoning. Semin Neurol. 2004;24:197-204.
35. Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur JG. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol Biomarkers Prev. 2005;14:731-734.
36. Holland N, Furlong C, Bastaki M, et al. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect. 2006;114:985-991.
37. Carmine A, Buervenich S, Sydow O, Anvret M, Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord. 2002;17:764-766.
38. Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E. Gln -> Arg 191 polymorphism of paraoxonase and Parkinson disease. Hum Hered. 1999;49:178-180.
39. Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson disease in a Finnish population. Neurosci Lett. 2004;367:168-170.
40. Kelada SN, Costa-Mallen P, Checkoway H, et al. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson disease. J Neurol Neurosurg Psychiatr. 2003;74:546-547.
41. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
42. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-66.
43. Mackness B, Mackness MI, Arrol S, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341-349.
44. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000;20:516-521.
45. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 1999;9:745-753.
46. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun. 1997;236:289-293.
47. Morimoto LM, White E, Newcomb PA. Selection bias in the assessment of gene-environment interaction in case-control studies. Am J Epidemiol. 2003;158:259-263.